Relative Bioavailability of Rosuvastatin and Dabigatran with BI 1323495

Phase 1, randomised, open-label trial of BI 1323495 in Non-Cystic Fibrosis Bronchiectasis (NCFB), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity up to 95 hours and Maximum Measured Concentration of the Analyte in Plasma up to 95 hours. Started Feb 2020; status: completed.